مقالات رزومه دکتر داریوش شیرانی

Homocysteine (Hcy) is a sulfur-containing amino acid derived from methionine. Several studies have suggested that plasma Hcy may be a useful biomarker of cardiovascular disease in human. There is limited information about serum homocysteine in heart diseases of dogs.

The present study aimed to assess the concentration of serum total Hcy and evaluate the relationship between its concentrations and serum levels of cholesterol, triglycerides, and activities of creatine phosphokinase and aspartate aminotransferase in small breed of dogs with endocardiosis.

For this purpose, a total of 15 dogs (seven males and eight females) with acquired endocardiosis were confirmed by clinical examination, auscultation, thoracic radiography, and echocardiography. In addition, 15 normal dogs of the similar age, breed, and weight were selected as the controls. All the examinations performed on the patients were carried out on the healthy dogs. Homocysteine was measured via an enzymatic method. Additionally, the activities of CPK and AST and the levels of cholesterol and triglycerides were assessed utiling commercial kits. Subsequently, the data were analyzed with t- student test and one- way ANOVA and Pearson’s linear correlation test was used to determine the relationship between serum homocysteine levels with triglycerides, cholesterol, CPK, and AST.

The results revealed no significant differences concerning serum homocysteine level and AST activity between the two groups; meanwhile, the increase in serum triglycerides and CPK activities in dogs with heart disease was statistically significant compared to that in the control group. However, there was no significant correlation between homocysteine and the other measured parameters.

The present study indicated that the role of homocysteine as a new risk factor associated with dog endocardiosis is questionable and it seems as if in human studies related to homocysteine and heart disease, the selection of dog as animal model requires further investigation.

Doxorubicin is one of the most widely used anticancer chemotherapeutic agents in small animal practice. The use of doxorubicin can cause cardiotoxicity, hepatotoxicity, neurotoxicity, and nephrotoxicity.

This study was carried out to evaluate the effects of ascorbic acid on doxorubicin hepatotoxicity in mice.

Twenty-four Balb/c mice were randomly divided into four groups. Group one received normal saline, group two received 100 mg/kg ascorbic acid, group three received 8 mg/kg doxorubicin and group four received ascorbic acid and doxorubicin intraperitoneally, with the same doses of groups 2 and 3. Twenty-one days after injection, the mice were euthanized. The activities of ALP, ALT, AST enzymes and total bilirubin levels in the serum samples were measured. Liver samples were evaluated histopathologically.

The activities of ALP, ALT, AST, and total bilirubin levels and histopathologic scores of hepatotoxicity were significantly lower in the group that received ascorbic acid + doxorubicin in comparison to those of the doxorubicin group.

Ascorbic acid may be useful in the prevention of doxorubicin hepatotoxicity in mice. Further studies are recommended for evaluation of the use of ascorbic acid in small animals.